Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Sanghwa Urm"
Filter
Filter
Article category
Publication year
Authors
Original Article
Analysis of Biologically Equivalent Dose of Stereotactic Body Radiotherapy for Primary and Metastatic Lung Tumors
Sungkwang Park, Sanghwa Urm, Heunglae Cho
Cancer Res Treat. 2014;46(4):403-410.   Published online July 17, 2014
DOI: https://doi.org/10.4143/crt.2013.168
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to determine the optimal biologically equivalent dose (BED) for stereotactic body radiotherapy (SBRT) by comparing local control rates in proportion to various total doses and fractionation schedules. Materials and Methods Thirty-four patients with early non-small-cell lung cancer and a single metastatic lung tumor were included in this study. Differences in local control rates were evaluated according to gender, primary tumor site, response, tumor size, and BED. For comparison of BEDs, the prescribed dose for SBRT was stratified according to three groups: high (BED > 146 Gy), medium to high (BED, 106 to 146 Gy), and low to medium (BED < 106 Gy). Results For all patients, the overall local control rate was 85.3% at two years after treatment. Five local recurrences were observed, and, notably, all of them were observed in the low to medium BED group. Significantly higher local control rates were observed for patients with a complete response than for those with a partial response or stable disease (p < 0.001). Twenty-six patients with a tumor size of < 3 cm showed no dose-response relationship in the low to medium, medium to high, and high BED groups, whereas eight patients with a tumor size of ≥ 3 cm showed a significant dose-response relationship. The observed 2-year local recurrence-free survival rates in patients with a tumor size of < 3 cm and in those with a tumor size of ≥ 3 cm were 96.2% and 50.0%, respectively, which were significantly different (p=0.007). Conclusion BED > 100 Gy is required in order to achieve a > 85% local control rate regardless of tumor size. The optimal dose for small tumors of < 3 cm appears to be within a range below 150 Gy BED. Escalation of BED to high levels (> 150 Gy) may be required for patients with a tumor size larger than 3 cm.

Citations

Citations to this article as recorded by  
  • The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy – a nationwide cohort study
    Julianne Cynthia de Ruiter, Vincent van der Noort, Judi Nani Annet van Diessen, Egbert Frederik Smit, Ronald Alphons Maria Damhuis, Koen Johan Hartemink, M.I. Amir, H. van Berkum, H. Bertens, M. Bindels, E.M. Bongers, R.C. Boshuizen, K. de Brake-de Jong,
    Lung Cancer.2024; 191: 107792.     CrossRef
  • Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group
    Gyu Sang Yoo, Sunmin Park, Chai Hong Rim, Won Kyung Cho, Ah Ram Chang, Young Seok Kim, Yong Chan Ahn, Eui Kyu Chie
    Current Oncology.2024; 31(6): 3239.     CrossRef
  • Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis
    Gustavo A. Viani, Andre G. Gouveia, Alexander V. Louie, Fabio Arcidiacono, Charles B. Simone, Theodoros Tsakiridis, Ana Carolina Hamamura, Paola Anselmo, Fabio Y. Moraes
    Radiotherapy and Oncology.2024; 201: 110439.     CrossRef
  • Treatment outcomes of stereotactic body radiation therapy for pulmonary metastasis from sarcoma: a multicenter, retrospective study
    Tae Hoon Lee, Hak Jae Kim, Jin Ho Kim, Mi-Sook Kim, Won Il Jang, Eunji Kim, Kyung Su Kim
    Radiation Oncology.2023;[Epub]     CrossRef
  • Dosimetric evaluation of SBRT treatment plans of non-central lung tumours: clinical experience
    Ernest Osei, Johnson Darko, Steph Swanson, Katrina Fleming, Ronald Snelgrove, Anmol Bhangu, Darin Gopaul
    Journal of Radiotherapy in Practice.2022; 21(2): 179.     CrossRef
  • Use of Multi-Site Radiation Therapy for Systemic Disease Control
    Roshal R. Patel, Vivek Verma, Hampartsoum B. Barsoumian, Matthew S. Ning, Stephen G. Chun, Chad Tang, Joe Y. Chang, Percy P. Lee, Saumil Gandhi, Peter Balter, Joe Dan Dunn, Dawei Chen, Nahum Puebla-Osorio, Maria Angelica Cortez, James W. Welsh
    International Journal of Radiation Oncology*Biology*Physics.2021; 109(2): 352.     CrossRef
  • Ablative Radiotherapy for Patients With Inoperable Pancreas Cancer—Ready for Prime Time?
    David P. Horowitz, Karyn Goodman, Lisa A. Kachnic
    JAMA Oncology.2021; 7(5): 687.     CrossRef
  • Evidence-Based Planning Target Volume Margin Reduction for Modern Lung Stereotactic Ablative Radiation Therapy Using Deformable Registration
    Katie Jasper, Baochang Liu, Robert Olson, Quinn Matthews
    Advances in Radiation Oncology.2021; 6(6): 100750.     CrossRef
  • Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus
    William Tyler Turchan, Sean P. Pitroda, Ralph R. Weichselbaum
    Clinical Cancer Research.2021; 27(19): 5188.     CrossRef
  • Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms
    Jingjing Kang, Matthew S. Ning, Han Feng, Hongqi Li, Houda Bahig, Eric D. Brooks, James W. Welsh, Rui Ye, Hongyu Miao, Joe Y. Chang
    International Journal of Radiation Oncology*Biology*Physics.2020; 106(1): 90.     CrossRef
  • Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation
    Stephen R. Grant, Xiudong Lei, Kenneth R. Hess, Grace L. Smith, Surena F. Matin, Christopher G. Wood, Quynh Nguyen, Steven J. Frank, Mitchell S. Anscher, Benjamin D. Smith, Jose A. Karam, Chad Tang
    Advances in Radiation Oncology.2020; 5(3): 495.     CrossRef
  • The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma
    Cameron M. Callaghan, Steven N. Seyedin, Imran H. Mohiuddin, Kelli L. Hawkes, Michael S. Petronek, Carryn M. Anderson, John M. Buatti, Mohammed M. Milhem, Varun Monga, Bryan G. Allen
    Radiation Research.2020; 194(2): 124.     CrossRef
  • Traitements locaux : indication et résultats dans les stades précoces
    L. Padovani, C. Massabeau, J. Khalifa, P. Habert, J.-Y. Gaubert
    Revue des Maladies Respiratoires Actualités.2020; 12(2): 2S79.     CrossRef
  • Maximum standardized uptake value at pre-treatment PET in estimating lung cancer progression after stereotactic body radiotherapy
    Jisun Park, Yunseon Choi, Ki Jung Ahn, Sung Kwang Park, Heunglae Cho, Ji Young Lee
    Radiation Oncology Journal.2019; 37(1): 30.     CrossRef
  • Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function
    Jia-Yang Lu, Pei-Xian Lin, Bao-Tian Huang
    Radiation Oncology.2019;[Epub]     CrossRef
  • La radiothérapie stéréotaxique: indication et résultats dans les stades précoces
    C. Massabeau, J. Khalifa
    Revue des Maladies Respiratoires Actualités.2019; 11(3): 255.     CrossRef
  • GTV volume estimation using different mode of computer tomography for lung tumors in stereotactic body radiation therapy
    Ramaa Lingaiah, Md Abbas Ali, Ummay Kulsum, Muhtasim Aziz Muneem, Karthick Raj Mani, Sharif Ahmed, Md. Shakilur Rahman, M Salahuddin
    Polish Journal of Medical Physics and Engineering.2019; 25(1): 29.     CrossRef
  • Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study
    Wan Jeon, Sung-Ja Ahn, Young-Chul Kim, In-Jae Oh, Chul-Kyu Park, Jae-Uk Jeong, Mee Sun Yoon, Ju-Young Song, Taek-Keun Nam, Woong-Ki Chung
    Japanese Journal of Clinical Oncology.2018; 48(2): 144.     CrossRef
  • Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions
    Meisong Ding, William Zollinger, Robert Ebeling, David Heard, Ryan Posey
    Journal of Applied Clinical Medical Physics.2018; 19(6): 226.     CrossRef
  • Oligometastatische Erkrankung des nichtkleinzelligen Lungenkarzinoms
    Severin Schmid, Bernward Passlick, Martin Stuschke, Frank Griesinger
    Der Onkologe.2018; 24(12): 992.     CrossRef
  • A feasibility study of spatiotemporally integrated radiotherapy using the LQ model
    M Kim, M H Phillips
    Physics in Medicine & Biology.2018; 63(24): 245016.     CrossRef
  • Dosimetric comparison of deep inspiration breath hold and free breathing technique in stereotactic body radiotherapy for localized lung tumor using Flattening Filter Free beam
    Karthick Raj Mani, Md. Anisuzzaman Bhuiyan, Md. Mahbub Alam, Sharif Ahmed, Mostafa Aziz Sumon, Ashim Kumar Sengupta, Md. Shakilur Rahman, Md. S. M. Azharul Islam
    Polish Journal of Medical Physics and Engineering.2018; 24(1): 15.     CrossRef
  • Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases
    J.H. Chang, S. Gandhidasan, R. Finnigan, D. Whalley, R. Nair, A. Herschtal, T. Eade, A. Kneebone, J. Ruben, M. Foote, S. Siva
    Clinical Oncology.2017; 29(7): e119.     CrossRef
  • Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy
    Bao-Tian Huang, Wu-Zhe Zhang, Li-Li Wu, Pei-Xian Lin, Jia-Yang Lu
    BioMed Research International.2017; 2017: 1.     CrossRef
  • The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer
    Eduardo Guerrero, Merina Ahmed
    Lung Cancer.2016; 92: 22.     CrossRef
  • Hypofractionated radiotherapy for medically inoperable stage I non‐small cell lung cancer
    Wei Jiang, Jian‐Yang Wang, Jing‐Bo Wang, Jun Liang, Zhou‐Guang Hui, Xiao‐Zhen Wang, Zong‐Mei Zhou, Lu‐Hua Wang
    Thoracic Cancer.2016; 7(3): 296.     CrossRef
  • Lung SBRT through Radiobiology
    Aime M. Gloi
    International Journal of Medical Physics, Clinical Engineering and Radiation Oncology.2016; 05(01): 78.     CrossRef
  • Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules
    Won Kyung Cho, Jae Myoung Noh, Yong Chan Ahn, Dongryul Oh, Hongryull Pyo
    Cancer Research and Treatment.2016; 48(4): 1187.     CrossRef
  • Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy
    Lina Zhao, Shouhao Zhou, Peter Balter, Chan Shen, Daniel R. Gomez, James D. Welsh, Steve H. Lin, Joe Y. Chang
    International Journal of Radiation Oncology*Biology*Physics.2016; 95(4): 1226.     CrossRef
  • Clinical characteristics and dose-volume histogram parameters associated with the development of pleural effusions in non-small cell lung cancer patients treated with chemoradiation therapy
    Matthew P. Deek, Sairaman Nagarajan, Sinae Kim, Inaya Ahmed, Shiby Paul, Eli D. Scher, Matthew Listo, Andrew Chen, Joseph Aisner, Sabiha Hussain, Bruce G. Haffty, Salma K. Jabbour
    Acta Oncologica.2016; 55(8): 1029.     CrossRef
  • Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced Chest Wall Pain
    Shaun U. Din, Eric L. Williams, Andrew Jackson, Kenneth E. Rosenzweig, Abraham J. Wu, Amanda Foster, Ellen D. Yorke, Andreas Rimner
    International Journal of Radiation Oncology*Biology*Physics.2015; 93(2): 418.     CrossRef
  • A feasibility study: Selection of a personalized radiotherapy fractionation schedule using spatiotemporal optimization
    Minsun Kim, Robert D. Stewart, Mark H. Phillips
    Medical Physics.2015; 42(11): 6671.     CrossRef
  • Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy
    Bao-Tian Huang, Jia-Yang Lu, Pei-Xian Lin, Jian-Zhou Chen, De-Rui Li, Chuang-Zhen Chen
    Scientific Reports.2015;[Epub]     CrossRef
  • A Theoretical Study: Selection of a Personalized Radiotherapy Fractionation Schedule Using Spatiotemporal Optimization
    Minsun Kim, Robert Stewart, Mark H Phillips
    SSRN Electronic Journal.2015;[Epub]     CrossRef
  • 12,801 View
  • 77 Download
  • 35 Web of Science
  • 34 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP